The incidence and pathogenesis of hypertension associated with a selection of predominantly targeted anticancer therapies, particularly inhibitors of the VEGF (vascular endothelial growth factor) pathway are reviewed. The gene discussed is VEGFA; the disease is hypertensive disorder.